Roivant Sciences Ltd. (ROIV)
Data as of , from SEC Form 4 filings.
See up to 3 months of ROIV. The 7-day demo opens the 1M and 3M ranges and puts ROIV on your watchlist.
Start 7-day demoLatest ROIV insider trades
About Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- LONDON
- 721
- 2021
- XNAS
ROIV Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 18 | 1,647,800 | $59.83M |
| Grant or award | 15 | 95,233 | |
| Option exercise | 23 | 3,275,500 | |
| Tax withholding / forfeiture | 12 | 203,364 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ROIV insider transactions (Form 4)
68141 Form 4 filings on record, the earliest from Oct 1, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Melissa B, Epperly - Director | Option exercise | Common Shares | 17,750 | $4.46 | $79K | |
| Melissa B, Epperly - Director | Open-market sale | Common Shares | 16,850 | $36.08 footnote F1 | $608K | |
| Melissa B, Epperly - Director | Open-market sale | Common Shares | 900 | $36.57 footnote F2 | $33K | |
| Melissa B, Epperly - Director | Option exercise | Stock Option (Right to Buy) | 17,750 | $0.00 | - | |
| ||||||
 Matthew Gline - Officer | Tax withholding / forfeiture | Common Shares | 76,171 footnote F1 | $36.57 | $2.79M | |
| ||||||
| Frank Torti - Officer | Tax withholding / forfeiture | Common Shares | 40,309 footnote F1 | $36.57 | $1.47M | |
| ||||||
| Mayukh Sukhatme - Officer | Tax withholding / forfeiture | Common Shares | 46,879 footnote F1 | $36.57 | $1.71M | |
| ||||||
| Eric Venker - Officer | Option exercise | Common Shares | 200,000 | $3.85 | $770K | |
| Eric Venker - Officer | Open-market sale | Common Shares | 200,000 | $36.62 footnote F1 | $7.32M | |
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| ||||||
 Jennifer Humes - Officer | Tax withholding / forfeiture | Common Shares | 3,880 footnote F1 | $39.77 | $154K | |
| ||||||
 Richard Pulik - Officer | Tax withholding / forfeiture | Common Shares | 2,129 footnote F1 | $39.77 | $85K | |
| ||||||
| Keith S. Manchester - Director | Grant or award | Common Shares | 5,054 footnote F1 | $0.00 footnote F1 | - | |
| Keith S. Manchester - Director | Grant or award | Stock Option (Right to Buy) | 10,531 | $0.00 | - | |
| ||||||
| Daniel Allen Gold - Director | Grant or award | Common Shares | 5,054 footnote F1 | $0.00 footnote F1 | - | |
| Daniel Allen Gold - Director | Grant or award | Stock Option (Right to Buy) | 10,531 | $0.00 | - | |
| ||||||
| Ilan Oren - Director | Grant or award | Stock Option (Right to Buy) | 10,531 | $0.00 | - | |
| Ilan Oren - Director | Grant or award | Common Shares | 5,054 footnote F1 | $0.00 footnote F1 | - | |
| ||||||
| James C. Momtazee - Director | Grant or award | Common Shares | 5,054 footnote F1 | $0.00 footnote F1 | - | |
| James C. Momtazee - Director | Grant or award | Stock Option (Right to Buy) | 10,531 | $0.00 | - | |
| ||||||
| Meghan Fitzgerald - Director | Grant or award | Common Shares | 5,054 footnote F1 | $0.00 footnote F1 | - | |
| Meghan Fitzgerald - Director | Grant or award | Stock Option (Right to Buy) | 10,531 | $0.00 | - | |
| ||||||
| Melissa B, Epperly - Director | Grant or award | Common Shares | 5,054 footnote F1 | $0.00 footnote F1 | - | |
| Melissa B, Epperly - Director | Grant or award | Stock Option (Right to Buy) | 10,531 | $0.00 | - | |
| ||||||
| Melissa B, Epperly - Director | Open-market sale | Common Shares | 4,338 | $39.65 | $172K | |
| Melissa B, Epperly - Director | Open-market sale | Common Shares | 600 | $40.38 | $24K | |
| Meghan Fitzgerald - Director | Open-market sale | Common Shares | 4,712 | $39.68 footnote F1 | $187K | |
| Meghan Fitzgerald - Director | Open-market sale | Common Shares | 400 | $40.45 footnote F2 | $16K | |
| ||||||
| Daniel Allen Gold - Director | Tax withholding / forfeiture | Common Shares | 5,133 footnote F1 | $40.94 | $210K | |
| ||||||
| Ilan Oren - Director | Tax withholding / forfeiture | Common Shares | 2,378 footnote F1 | $40.94 | $97K | |
| ||||||
| Melissa B, Epperly - Director | Tax withholding / forfeiture | Common Shares | 2,179 footnote F1 | $40.94 | $89K | |
| ||||||
| Meghan Fitzgerald - Director | Tax withholding / forfeiture | Common Shares | 1,743 footnote F1 | $40.94 | $71K | |
| ||||||
| James C. Momtazee - Director | Tax withholding / forfeiture | Common Shares | 2,905 footnote F1 | $40.94 | $119K | |
| ||||||
| Meghan Fitzgerald - Director | Option exercise | Common Shares | 20,000 | $8.80 | $176K | |
| Meghan Fitzgerald - Director | Open-market sale | Common Shares | 20,000 | $39.90 footnote F1 | $798K | |
| Meghan Fitzgerald - Director | Option exercise | Stock Option (Right to Buy) | 20,000 | $0.00 | - | |
| ||||||
| Eric Venker - Officer | Option exercise | Common Shares | 200,000 | $3.85 | $770K | |
| Eric Venker - Officer | Open-market sale | Common Shares | 166,182 | $35.63 footnote F1 | $5.92M | |
| Eric Venker - Officer | Open-market sale | Common Shares | 33,818 | $36.44 footnote F2 | $1.23M | |
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| ||||||
| Richard Pulik - Officer | Tax withholding / forfeiture | Common Shares | 5,749 footnote F1 | $36.84 | $212K | |
| ||||||
| Eric Venker - Officer | Tax withholding / forfeiture | Common Shares | 13,909 footnote F1 | $36.84 | $512K | |
| ||||||
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 17,519 | $37.30 footnote F2 | $653K | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 144,756 | $3.85 | $557K | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 144,756 | $36.48 footnote F3 | $5.28M | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 17,519 | $3.85 | $67K | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 172,899 | $3.85 | $666K | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 172,899 | $37.17 footnote F1 | $6.43M | |
| Mayukh Sukhatme - Officer | Option exercise | Stock Option (Right to Buy) | 172,899 | $0.00 | - | |
| Mayukh Sukhatme - Officer | Option exercise | Stock Option (Right to Buy) | 17,519 | $0.00 | - | |
| Mayukh Sukhatme - Officer | Option exercise | Stock Option (Right to Buy) | 144,756 | $0.00 | - | |
| ||||||
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 243,177 | $3.85 | $936K | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 243,177 | $36.23 footnote F1 | $8.81M | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 284,707 | $3.85 | $1.10M | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 284,707 | $36.25 footnote F2 | $10.32M | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 105,141 | $3.85 | $405K | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 105,141 | $36.59 footnote F3 | $3.85M | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 31,801 | $3.85 | $122K | |
| Mayukh Sukhatme - Officer | Open-market sale | Common Shares | 31,801 | $37.18 footnote F4 | $1.18M | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 243,177 | $0.00 | - | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 284,707 | $0.00 | - | |
| Mayukh Sukhatme - Officer | Option exercise | Common Shares | 136,942 | $0.00 | - | |
| ||||||
| Eric Venker - Officer | Option exercise | Common Shares | 200,000 | $3.85 | $770K | |
| Eric Venker - Officer | Open-market sale | Common Shares | 200,000 | $34.95 footnote F1 | $6.99M | |
| Eric Venker - Officer | Option exercise | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
| ||||||
| James C. Momtazee | Grant or award | Common Shares | 405 footnote F1 | $0.00 footnote F1 | - | |
| ||||||
| Melissa B, Epperly | Grant or award | Common Shares | 543 footnote F1 | $0.00 footnote F1 | - | |
| ||||||
| Ilan Oren | Grant or award | Common Shares | 775 footnote F1 | $0.00 footnote F1 | - | |
| ||||||
Item 5.07, 9.01
Item 7.01, 9.01
Item 8.01, 9.01
Item 7.01, 9.01
Item 2.02, 9.01
Recent ROIV Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Venker Eric | Officer | 200,000 | $7.32M | View on EDGAR | |
| MELISSA EPPERLY | Director | 22,688 | $931K | View on EDGAR | |
| MEGHAN FITZGERALD | Officer | 5,112 | $210K | View on EDGAR |
Stock trades in ROIV disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Lisa C. McClainRepublican, MI-09 | Sale | $1,001 to $15,000 | Spouse | 21 days | Original filing | ||
| Lisa C. McClainRepublican, MI-09 | Purchase | $1,001 to $15,000 | Spouse | 22 days | Original filing | ||
| Lisa C. McClainRepublican, MI-09 | Sale | $1,001 to $15,000 | Spouse | 22 days | Original filing |
House of Representatives Periodic Transaction Reports from 2024. Senate filings are not included yet. The full history of ROIV beside its insider purchases is in the Congress Tracker.
ROIV insider trading FAQ
What is the latest insider trade for ROIV?
Roivant Sciences Ltd. (ROIV) had 30 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for ROIV runs to 141 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ROIV stock?
No insider purchases of ROIV were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling ROIV stock?
18 insider sales of ROIV were filed in the last 90 days, totaling $59.83M.
Where can I see ROIV SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ROIV Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Melissa B, Epperly view on EDGAR
- - Matthew Gline view on EDGAR
- - Frank Torti view on EDGAR
- - Mayukh Sukhatme view on EDGAR
- - Eric Venker view on EDGAR
- - Jennifer Humes view on EDGAR
- - Richard Pulik view on EDGAR
- - Keith S. Manchester view on EDGAR
- - Daniel Allen Gold view on EDGAR
- - Ilan Oren view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ROIV's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ROIV with a 7-day demo
- ROIV on your watchlist
- Every ROIV Form 4 filing on record
- Up to 3 months of ROIV price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.